How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) posted its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company earned $0.54 million during the quarter, compared to analyst estimates of $0.25 million. During the same period last year, the company earned ($0.60) EPS.

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com . Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD) , Eiger BioPharmaceuticals (EIGR) , Exelixis (EXEL) , ACADIA Pharmaceuticals (ACAD) , Nektar Therapeutics (NKTR) , TG Therapeutics (TGTX) , Celldex Therapeutics (CLDX) , Amicus Therapeutics (FOLD) , Global Blood Therapeutics (GBT) and Intel (INTC) .

NASDAQ:CNCE

Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis

→ Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad)

Free CNCE Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $8.37
▼
$8.37
50-Day Range: $8.33
▼
$8.40
52-Week Range: $2.66
▼
$8.55

Volume: N/A
Average Volume: 2.97 million shs
Market Capitalization: $401.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Ad Allegiance Gold

Does this make you sick?

The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.

Get your Free Wealth Protection Kit

About Concert Pharmaceuticals Stock (NASDAQ:CNCE)

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Ad Allegiance Gold

Does this make you sick?

Get your Free Wealth Protection Kit

CNCE Stock News Headlines

April 7, 2024 | nytimes.com

The Best Bag to Bring to a Concert Is Actually a Running Belt

April 1, 2024 | au.news.yahoo.com

Teresa Giudice and Her Lookalike Daughters Glam Up for Nicki Minaj Concert: ‘New Jersey Takes Gag City’

March 30, 2024 | msn.com

Video: Pharma boss apologises after pill linked to five deaths and over 100 hospitalisations

October 28, 2023 | nypost.com

NFL pushed networks to air Taylor Swift concert film promos — for free

October 2, 2023 | msn.com

Beyoncé 'Renaissance' Movie Tickets and How To See Concert Film in Theaters

September 15, 2023 | usatoday.com

Taylor Swift 'overjoyed' to release Eras Tour concert movie: How to watch

September 12, 2023 | usatoday.com

Bruce Springsteen forced to postpone Philadelphia concerts with E Street Band due to illness

August 7, 2023 | usatoday.com

Miranda Lambert scolds fans for taking selfies during her concert: 'I don't like it'

August 6, 2023 | usatoday.com

The worst people at concerts, from self-involved selfie takers to nonstop filmers

July 25, 2023 | bbc.co.uk

Highlights from King Charles III Coronation concert

July 17, 2023 | usatoday.com

Fan throws bag of ashes at Pink during tour concert

July 4, 2023 | ca.style.yahoo.com

Birds Papaya stuns fans in Shania Twain-inspired outfit for concert

May 7, 2023 | bbc.com

How to watch the Coronation and Coronation Concert on BBC TV and iPlayer and listen on radio and BBC Sounds

May 4, 2023 | bbc.co.uk

Ticket ballot for the Coronation Concert

March 26, 2023 | msn.com

Who is Florence Price? Find out at a free Philadelphia Orchestra concert Saturday

February 15, 2023 | finance.yahoo.com

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

February 6, 2023 | markets.businessinsider.com

Analysts Are Neutral on These Healthcare Stocks: Zimmer Biomet Holdings (ZBH), Concert Pharma (CNCE)

January 30, 2023 | benzinga.com

Moore Kuehn Encourages KERN, CNCE, AQUA and ANGN Investors to Contact Law Firm

January 23, 2023 | finance.yahoo.com

Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer

January 22, 2023 | msn.com

5 big deal reports: Sun Pharma’s $576M pact for Concert Pharma

January 20, 2023 | finance.yahoo.com

Why Concert Pharmaceuticals Stock Rocketed Higher This Week

January 20, 2023 | marketwatch.com

CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders

January 19, 2023 | benzinga.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Concert Pharmaceuticals, Inc. (CNCE)

January 19, 2023 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun Pharma

January 19, 2023 | marketwatch.com

Concert Pharmaceuticals Shares Rally on Takeover by Sun >CNCE

See More Headlines

Company Calendar

Last Earnings: 11/09/2021
Today: 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CNCE
CUSIP: N/A
CIK: 1367920
Web: www.concertpharma.com
Phone: (781) 860-0045
Fax: 302-636-5454
Employees: 64
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-80,050,000.00
Net Margins: N/A
Pretax Margin: -300,735.69%
Return on Equity: -109.43%
Return on Assets: -76.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.03
Quick Ratio: 9.03

Sales & Book Value

Annual Sales: $32.58 million
Price / Sales: 12.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.24 per share
Price / Book: 2.58

Miscellaneous

Outstanding Shares: 47,940,000
Free Float: 42,507,000
Market Cap: $401.26 million
Optionable: Optionable
Beta: 0.52

Key Executives

Roger D. Tung
President, Chief Executive Officer & Director
Nancy Stuart
Chief Operating Officer
Marc A. Becker
Chief Financial & Accounting Officer
Mitch K. Goldenberg
VP-Information Technology & Infrastructure
Virginia Braman
Vice President-Clinical Development

Key Competitors

View All Competitors

CNCE Stock Analysis - Frequently Asked Questions

How were Concert Pharmaceuticals' earnings last quarter?: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) posted its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company earned $0.54 million during the quarter, compared to analyst estimates of $0.25 million. During the same period last year, the company earned ($0.60) EPS.
What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?: 1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Concert Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC).

This page (NASDAQ:CNCE) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis

About Concert Pharmaceuticals Stock (NASDAQ:CNCE)

CNCE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CNCE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info